IRIS Accounts Production v24.2.0.383 12997974 Board of Directors 1.4.23 31.3.24 31.3.24 0 0 false true false false true false A Ordinary 1.00000 B Ordinary 1.00000 C Ordinary 1.00000 D Ordinary 1.00000 7815 26629 209468 208444 174000 174000 43283 7815 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh129979742023-03-31129979742024-03-31129979742023-04-012024-03-31129979742022-03-31129979742022-04-012023-03-31129979742023-03-3112997974ns15:EnglandWales2023-04-012024-03-3112997974ns14:PoundSterling2023-04-012024-03-3112997974ns10:Director12023-04-012024-03-3112997974ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3112997974ns10:SmallEntities2023-04-012024-03-3112997974ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3112997974ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3112997974ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3112997974ns10:FullAccounts2023-04-012024-03-3112997974ns10:OrdinaryShareClass22023-04-012024-03-3112997974ns10:OrdinaryShareClass32023-04-012024-03-3112997974ns10:OrdinaryShareClass42023-04-012024-03-3112997974ns10:OrdinaryShareClass52023-04-012024-03-311299797441ns10:Director12023-03-311299797441ns10:Director12022-03-311299797441ns10:Director12023-04-012024-03-311299797441ns10:Director12022-04-012023-03-311299797441ns10:Director12024-03-311299797441ns10:Director12023-03-3112997974ns10:Director22023-04-012024-03-3112997974ns10:RegisteredOffice2023-04-012024-03-3112997974ns5:CurrentFinancialInstruments2024-03-3112997974ns5:CurrentFinancialInstruments2023-03-3112997974ns5:ShareCapital2024-03-3112997974ns5:ShareCapital2023-03-3112997974ns5:RetainedEarningsAccumulatedLosses2024-03-3112997974ns5:RetainedEarningsAccumulatedLosses2023-03-3112997974ns5:CostValuation2023-03-3112997974ns5:DisposalsRepaymentsInvestments2024-03-3112997974ns5:CostValuation2024-03-3112997974ns10:OrdinaryShareClass22024-03-3112997974ns10:OrdinaryShareClass32024-03-3112997974ns10:OrdinaryShareClass42024-03-3112997974ns10:OrdinaryShareClass52024-03-3112997974ns10:Director222023-03-3112997974ns10:Director222022-03-3112997974ns10:Director222023-04-012024-03-3112997974ns10:Director222022-04-012023-03-3112997974ns10:Director222024-03-3112997974ns10:Director222023-03-31
REGISTERED NUMBER: 12997974 (England and Wales)












UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

FOR

YORKSHIRE PHARMA HOLDINGS LTD

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


YORKSHIRE PHARMA HOLDINGS LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTORS: A K Atkinson
C H E Atkinson





REGISTERED OFFICE: 12 Victoria Road
Barnsley
South Yorkshire
S70 2BB





REGISTERED NUMBER: 12997974 (England and Wales)





ACCOUNTANTS: Gibson Booth Limited
12 Victoria Road
Barnsley
South Yorkshire
S70 2BB

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

BALANCE SHEET
31 MARCH 2024

31.3.24 31.3.23
Notes £    £    £    £   
FIXED ASSETS
Investments 4 4,018,595 4,226,595

CURRENT ASSETS
Debtors 5 43,283 7,815
Cash at bank 100 100
43,383 7,915
CREDITORS
Amounts falling due within one year 6 669,772 1,240,563
NET CURRENT LIABILITIES (626,389 ) (1,232,648 )
TOTAL ASSETS LESS CURRENT LIABILITIES 3,392,206 2,993,947

CAPITAL AND RESERVES
Called up share capital 7 2,600,099 2,600,099
Retained earnings 792,107 393,848
SHAREHOLDERS' FUNDS 3,392,206 2,993,947

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

BALANCE SHEET - continued
31 MARCH 2024


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 September 2024 and were signed on its behalf by:





A K Atkinson - Director


YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1. STATUTORY INFORMATION

Yorkshire Pharma Holdings Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest pound.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The Financial Statements contain information about Fleet Support Holdings Limited as an individual company and do not contain consolidated financial information as the parent of a group . The company has taken the option under Section 398 of the Companies Act 2006 not to prepare financial statements.

Significant judgements and estimates
No judgements have been made in the process of applying the below accounting policies that have had the most significant effect on amounts recognised in the financial statements.

There are no key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at historic cost. The fair value of investments in subsidiary undertakings, in the opinion of the directors, cannot be measured reliably without undue cost or effort.

As such, investments in subsidiary undertakings are accounted for using the cost model.

Regular impairment reviews are undertaken by the directors.


YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 April 2023 4,226,595
Disposals (208,000 )
At 31 March 2024 4,018,595
NET BOOK VALUE
At 31 March 2024 4,018,595
At 31 March 2023 4,226,595

YORKSHIRE PHARMA HOLDINGS LTD (REGISTERED NUMBER: 12997974)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Directors' current accounts 43,283 7,815

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Amounts owed to group undertakings 666,772 1,163,563
Other creditors 3,000 77,000
669,772 1,240,563

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.3.24 31.3.23
value: £    £   
1,170,045 A Ordinary £1 2,600,044 2,600,044
1,170,044 B Ordinary £1 45 45
130,005 C Ordinary £1 5 5
130,005 D Ordinary £1 5 5
2,600,099 2,600,099

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 March 2024 and 31 March 2023:

31.3.24 31.3.23
£    £   
C H E Atkinson and A K Atkinson
Balance outstanding at start of year 7,815 (26,629 )
Amounts advanced 209,468 208,444
Amounts repaid (174,000 ) (174,000 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 43,283 7,815